# Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Source: https://onco.cc/trials/nct04093167/  
OnCo record `nct04093167` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of pembrolizumab in lung cancer, run by Canadian Cancer Trials Group, active but no longer recruiting.

## Summary

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer is a phase 2/3, randomised interventional study registered as NCT04093167 by Canadian Cancer Trials Group, with a registry enrolment figure of 53 participants, started 2020-05-26 and due to reach its primary completion in 2026-12-31. Interventions recorded: Pembrolizumab. Conditions listed: Lung Cancer. Primary outcome: Stage 1: Concordance rate between molecular response and radiologic response; Stage 2: Phase II Progression-Free Survival (PFS); Stage 2: Phase III Overall Survival. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed metastatic NSCLC". Sites: Canada, United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT04093167
- Phase: 2/3
- Setting: A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
- Sponsor: Canadian Cancer Trials Group
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT04093167: https://clinicaltrials.gov/study/NCT04093167

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Canadian Cancer Trials Group (CCTG)](https://onco.cc/companies/cctg/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04093167.json